Cargando…
Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
BACKGROUND: Obesity and type 2 diabetes are drivers of non‐alcoholic fatty liver disease (NAFLD). Glucagon‐like peptide‐1 analogues effectively treat obesity and type 2 diabetes and may offer potential for NAFLD treatment. AIM: To evaluate the effect of the glucagon‐like peptide‐1 analogue, semaglut...
Autores principales: | Newsome, Philip, Francque, Sven, Harrison, Stephen, Ratziu, Vlad, Van Gaal, Luc, Calanna, Salvatore, Hansen, Morten, Linder, Martin, Sanyal, Arun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617813/ https://www.ncbi.nlm.nih.gov/pubmed/31246368 http://dx.doi.org/10.1111/apt.15316 |
Ejemplares similares
-
Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis
por: McPherson, Stuart, et al.
Publicado: (2017) -
Ten Years of Vildagliptin
por: Del Prato, Stefano
Publicado: (2017) -
The Vildagliptin Experience — 25 Years Since the Initiation of the Novartis Glucagon-like Peptide-1 Based Therapy Programme and 10 Years Since the First Vildagliptin Registration
por: Foley, James E, et al.
Publicado: (2017) -
Dipeptidyl Peptidase-4 Inhibitor Development and Post-authorisation Programme for Vildagliptin — Clinical Evidence for Optimised Management of Chronic Diseases Beyond Type 2 Diabetes
por: Strain, William David, et al.
Publicado: (2017) -
Clinical Safety and Tolerability of Vildagliptin — Insights from Randomised Trials, Observational Studies and Post-marketing Surveillance
por: Mathieu, Chantal, et al.
Publicado: (2017)